vs
Organogenesis Holdings Inc.（ORGO）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Organogenesis Holdings Inc.的1.8倍（$411.1M vs $225.6M），UiPath, Inc.净利率更高（48.4% vs 19.4%，领先29.0%），Organogenesis Holdings Inc.同比增速更快（78.1% vs 15.9%），Organogenesis Holdings Inc.自由现金流更多（$34.8M vs $25.1M），过去两年Organogenesis Holdings Inc.的营收复合增速更高（43.2% vs 0.7%）
Organogenesis Holdings Inc.是一家领先的再生医学企业，专注于开发、生产用于伤口护理、外科修复、运动医学和皮肤病领域的先进治疗产品，主要服务美国及部分国际市场的医疗机构与患者，提供经临床验证的医疗解决方案。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
ORGO vs PATH — 直观对比
营收规模更大
PATH
是对方的1.8倍
$225.6M
营收增速更快
ORGO
高出62.2%
15.9%
净利率更高
PATH
高出29.0%
19.4%
自由现金流更多
ORGO
多$9.7M
$25.1M
两年增速更快
ORGO
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $225.6M | $411.1M |
| 净利润 | $43.7M | $198.8M |
| 毛利率 | — | 83.3% |
| 营业利润率 | 28.1% | 3.2% |
| 净利率 | 19.4% | 48.4% |
| 营收同比 | 78.1% | 15.9% |
| 净利润同比 | 469.5% | 1966.2% |
| 每股收益（稀释后） | $0.31 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ORGOPATH
| Q4 25 | $225.6M | $411.1M | ||
| Q3 25 | $150.9M | $361.7M | ||
| Q2 25 | $101.0M | $356.6M | ||
| Q1 25 | $86.7M | $423.6M | ||
| Q4 24 | $126.7M | $354.7M | ||
| Q3 24 | $115.2M | $316.3M | ||
| Q2 24 | $130.2M | $335.1M | ||
| Q1 24 | $110.0M | $405.3M |
净利润ORGOPATH
| Q4 25 | $43.7M | $198.8M | ||
| Q3 25 | $21.6M | $1.6M | ||
| Q2 25 | $-9.4M | $-22.6M | ||
| Q1 25 | $-18.8M | $51.8M | ||
| Q4 24 | $7.7M | $-10.7M | ||
| Q3 24 | $12.3M | $-86.1M | ||
| Q2 24 | $-17.0M | $-28.7M | ||
| Q1 24 | $-2.1M | $33.9M |
毛利率ORGOPATH
| Q4 25 | — | 83.3% | ||
| Q3 25 | — | 82.2% | ||
| Q2 25 | — | 82.1% | ||
| Q1 25 | 72.6% | 84.8% | ||
| Q4 24 | 75.5% | 82.0% | ||
| Q3 24 | 76.7% | 80.0% | ||
| Q2 24 | 77.6% | 83.5% | ||
| Q1 24 | 73.9% | 86.8% |
营业利润率ORGOPATH
| Q4 25 | 28.1% | 3.2% | ||
| Q3 25 | 13.7% | -5.6% | ||
| Q2 25 | -12.5% | -4.6% | ||
| Q1 25 | -30.9% | 7.9% | ||
| Q4 24 | 8.1% | -12.2% | ||
| Q3 24 | 5.4% | -32.7% | ||
| Q2 24 | -10.7% | -14.8% | ||
| Q1 24 | -3.5% | 3.7% |
净利率ORGOPATH
| Q4 25 | 19.4% | 48.4% | ||
| Q3 25 | 14.3% | 0.4% | ||
| Q2 25 | -9.3% | -6.3% | ||
| Q1 25 | -21.7% | 12.2% | ||
| Q4 24 | 6.1% | -3.0% | ||
| Q3 24 | 10.7% | -27.2% | ||
| Q2 24 | -13.1% | -8.6% | ||
| Q1 24 | -1.9% | 8.4% |
每股收益（稀释后）ORGOPATH
| Q4 25 | $0.31 | $0.37 | ||
| Q3 25 | $0.11 | $0.00 | ||
| Q2 25 | $-0.10 | $-0.04 | ||
| Q1 25 | $-0.17 | $0.09 | ||
| Q4 24 | $0.05 | $-0.02 | ||
| Q3 24 | $0.09 | $-0.15 | ||
| Q2 24 | $-0.13 | $-0.05 | ||
| Q1 24 | $-0.02 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.7M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $300.1M | $1.9B |
| 总资产 | $598.7M | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ORGOPATH
| Q4 25 | $93.7M | $1.4B | ||
| Q3 25 | $63.7M | $1.4B | ||
| Q2 25 | $73.1M | $1.6B | ||
| Q1 25 | $110.0M | $1.6B | ||
| Q4 24 | $135.6M | $1.6B | ||
| Q3 24 | $94.3M | $1.7B | ||
| Q2 24 | $89.9M | $1.9B | ||
| Q1 24 | $88.6M | $1.9B |
总债务ORGOPATH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $62.3M | — | ||
| Q2 24 | $63.8M | — | ||
| Q1 24 | $65.2M | — |
股东权益ORGOPATH
| Q4 25 | $300.1M | $1.9B | ||
| Q3 25 | $255.1M | $1.7B | ||
| Q2 25 | $233.2M | $1.7B | ||
| Q1 25 | $242.9M | $1.8B | ||
| Q4 24 | $262.9M | $1.7B | ||
| Q3 24 | $278.5M | $1.8B | ||
| Q2 24 | $263.5M | $2.0B | ||
| Q1 24 | $278.0M | $2.0B |
总资产ORGOPATH
| Q4 25 | $598.7M | $2.9B | ||
| Q3 25 | $509.8M | $2.6B | ||
| Q2 25 | $461.1M | $2.6B | ||
| Q1 25 | $467.4M | $2.9B | ||
| Q4 24 | $497.9M | $2.7B | ||
| Q3 24 | $446.3M | $2.7B | ||
| Q2 24 | $443.2M | $2.8B | ||
| Q1 24 | $458.5M | $3.0B |
负债/权益比ORGOPATH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.22× | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | 0.23× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $39.4M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $34.8M | $25.1M |
| 自由现金流率自由现金流/营收 | 15.4% | 6.1% |
| 资本支出强度资本支出/营收 | 2.1% | 0.8% |
| 现金转化率经营现金流/净利润 | 0.90× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $-24.5M | — |
8季度趋势，按日历期对齐
经营现金流ORGOPATH
| Q4 25 | $39.4M | $28.3M | ||
| Q3 25 | $3.1M | $41.6M | ||
| Q2 25 | $-32.9M | $119.0M | ||
| Q1 25 | $-19.9M | $146.1M | ||
| Q4 24 | $10.9M | $28.1M | ||
| Q3 24 | $8.7M | $46.4M | ||
| Q2 24 | $4.7M | $100.0M | ||
| Q1 24 | $-10.2M | $145.6M |
自由现金流ORGOPATH
| Q4 25 | $34.8M | $25.1M | ||
| Q3 25 | $844.0K | — | ||
| Q2 25 | $-36.5M | $106.2M | ||
| Q1 25 | $-23.6M | $138.7M | ||
| Q4 24 | $7.6M | $23.2M | ||
| Q3 24 | $6.1M | $45.0M | ||
| Q2 24 | $2.9M | $98.8M | ||
| Q1 24 | $-12.4M | $141.8M |
自由现金流率ORGOPATH
| Q4 25 | 15.4% | 6.1% | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -36.1% | 29.8% | ||
| Q1 25 | -27.2% | 32.7% | ||
| Q4 24 | 6.0% | 6.5% | ||
| Q3 24 | 5.3% | 14.2% | ||
| Q2 24 | 2.2% | 29.5% | ||
| Q1 24 | -11.3% | 35.0% |
资本支出强度ORGOPATH
| Q4 25 | 2.1% | 0.8% | ||
| Q3 25 | 1.5% | 0.0% | ||
| Q2 25 | 3.6% | 3.6% | ||
| Q1 25 | 4.2% | 1.7% | ||
| Q4 24 | 2.7% | 1.4% | ||
| Q3 24 | 2.2% | 0.4% | ||
| Q2 24 | 1.4% | 0.4% | ||
| Q1 24 | 2.0% | 0.9% |
现金转化率ORGOPATH
| Q4 25 | 0.90× | 0.14× | ||
| Q3 25 | 0.14× | 26.25× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.82× | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 0.71× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ORGO
暂无分部数据
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
